MKI67 and breast carcinoma: The Ki-67 ≥ 20% threshold used in monarchE was based on the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015-accepted Ki-67 levels of 10 to 20% to indicate an intermediate risk group (interpreted in the light of local laboratory values) and 20 to 29% to indicate a higher risk “luminal B-like” disease [14], which may be appropriate for adjuvant CT.